Products for Research Use Only

PAWI-2

CAT: 0804-HY-123929-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-123929-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
PAWI-2 is a p53-Activator and Wnt Inhibitor. PAWI-2 inhibits β3-KRAS signaling independent of KRAS. PAWI-2 selectively inhibits phosphorylation of TBK1. PAWI-2 activates apoptosis (activation of caspase-3/7), and induces PARP cleavage. PAWI-2 promotes optineurin translocation into the nucleus and causes G2/M arrest. PAWI-2 reverses cancer stemness and overcomes drug resistance in an integrin β3 KRAS-dependent human pancreatic cancer stem cells (hPCSCs) . PAWI-2 inhibits growth of tumors from hPCSCs in orthopic xenograft mice model[1][2].
CAS Number
1448427-02-8
UNSPSC
12352005
Target
Apoptosis; Caspase; IKK; MDM-2/p53; Wnt
Type
Reference compound
Related Pathways
Apoptosis; NF-κB; Stem Cell/Wnt
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/pawi-2.html
Purity
99.29
Smiles
O=C1N(C2=CC=C(S(=O)(N3CCN(C)C4=C3C=CC=C4)=O)C=C2)CCC1
Molecular Formula
C19H21N3O3S
Molecular Weight
371.45
References & Citations
[1]Cashman JR, et al. Effect of PAWI-2 on pancreatic cancer stem cell tumors. Invest New Drugs. 2024 May 25. |[2]Cheng J, et al. PAWI-2 overcomes tumor stemness and drug resistance via cell cycle arrest in integrin β3-KRAS-dependent pancreatic cancer stem cells. Sci Rep. 2020 Jun 8;10 (1) :9162.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, stored under nitrogen)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
Caspase 3; Caspase 7

Popular Products